Floatz logo

Ranolazine

Bone Metastases

University of Colorado, DenverSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Bone Metastases cohort.

Asset / SponsorPhaseRating
Ibandronate
Kelly Fitzgerald, MD
Phase 4BBB
Denosumab
Kelly Fitzgerald, MD
Phase 4BBB
Zoledronate
Kelly Fitzgerald, MD
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 3BB
Zometa
Sun Yat-sen University
Phase 4BB

View all 50 →

Same molecule, other indications

Ranolazine is also rated in:

myocardial ischemiaDormant
A
Indicative ·
82 / 100
View asset →
coronary artery disorderDormant
BBB
Indicative ·
75 / 100
View asset →
myocardial ischemiaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →